Overall, the data from both pharmacological inhibition of histone methylation and comprehensive profiling of histone modifications support that the H3K36Me2 hypermethylation, driven by synergy between TGF-β and TNF-α, is implicated in MMP-9 overexpression in late-stage breast cancer MDA-MB-231 cell model. Here, TGFB1 is linked to breast cancer.